Urothelial Cancer Genomics
51 – 60 of 67
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
(
- Contribution to journal › Debate/Note/Editorial
- 2016
-
Mark
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
(
- Contribution to journal › Article
- 2015
-
Mark
Biological determinants of bladder cancer gene expression subtypes.
(
- Contribution to journal › Article
-
Mark
Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma.
(
- Contribution to journal › Article
-
Mark
Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.
(
- Contribution to journal › Article
-
Mark
Heterogeneous Challenges for Urologic Cancers.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
(
- Contribution to journal › Article
-
Mark
On Molecular Classification of Bladder Cancer: Out of One, Many.
(
- Contribution to journal › Debate/Note/Editorial
- 2014
-
Mark
Infiltration of CD3(+) and CD68(+) cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.
(
- Contribution to journal › Article
- 2013
-
Mark
Detailed Analysis of Focal Chromosome Arm 1q and 6p Amplifications in Urothelial Carcinoma Reveals Complex Genomic Events on 1q, and SOX4 as a Possible Auxiliary Target on 6p.
(
- Contribution to journal › Article